Gilead signed long time ago a deal for volume licensing of Velpatasvir with indian companies that are already in deal for Sofosbuvir production. Can't wait for Sof/Vel single pill for cca 10$ :)
I wonder whats the plan with Gilead's clinical trials of Sof+Vel+GS-9857. Seems they are targeting even shorter tx (6w only?) with this potent DAA combo.
Cinnamon Girl said
Oct 14, 2015
Yes, excellent data from these trials. Hopefully we`re slowly moving towards a time when genotype testing will not be so relevant as more new treatments come out which are effective across all types.
Thanks for posting it,Tig.
mallani said
Oct 14, 2015
Great results from a great Company.
Now for FDA approval and the Geno 3's may join the party.
Please make it affordable.
wmlj1960 said
Oct 9, 2015
I read it yesterday and my thoughts were along the lines of about how quick they are making advancements in treatment of HCV in recent times and how it will likely be in the near future when 100% effective treatment will be common as well as a vaccination to prevent initial infection. It gives me a confident feeling that HCV will be eradicated for our young as well as future generations. Thanks for the link Tig!
Tig said
Oct 9, 2015
I was surprised there were no comments on this, so I'm bumping this up just in case it was missed yesterday. We've been waiting for these results, don't miss the promising news! This will be the next silver bullet from Gilead. If you're considering treatment in the near future, this may be your ticket on the next train to SVRville.
Tig said
Oct 8, 2015
Some very good news indeed! WOOT!!
"FOSTER CITY, Calif.--(BUSINESS WIRE)--Sep. 21, 2015-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced topline results from four international Phase 3 clinical studies (ASTRAL-1, ASTRAL-2, ASTRAL-3 and ASTRAL-4) evaluating a once-daily, fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF) with velpatasvir (VEL), an investigational pangenotypic NS5Ainhibitor, for the treatment of genotype 1-6 chronic hepatitis C virus (HCV) infection"
Gilead signed long time ago a deal for volume licensing of Velpatasvir with indian companies that are already in deal for Sofosbuvir production. Can't wait for Sof/Vel single pill for cca 10$ :)
I wonder whats the plan with Gilead's clinical trials of Sof+Vel+GS-9857. Seems they are targeting even shorter tx (6w only?) with this potent DAA combo.
Yes, excellent data from these trials. Hopefully we`re slowly moving towards a time when genotype testing will not be so relevant as more new treatments come out which are effective across all types.
Thanks for posting it,Tig.
Great results from a great Company.
Now for FDA approval and the Geno 3's may join the party.
Please make it affordable.
I read it yesterday and my thoughts were along the lines of about how quick they are making advancements in treatment of HCV in recent times and how it will likely be in the near future when 100% effective treatment will be common as well as a vaccination to prevent initial infection. It gives me a confident feeling that HCV will be eradicated for our young as well as future generations. Thanks for the link Tig!
I was surprised there were no comments on this, so I'm bumping this up just in case it was missed yesterday. We've been waiting for these results, don't miss the promising news! This will be the next silver bullet from Gilead. If you're considering treatment in the near future, this may be your ticket on the next train to SVRville.
Some very good news indeed! WOOT!!
"FOSTER CITY, Calif.--(BUSINESS WIRE)--Sep. 21, 2015-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced topline results from four international Phase 3 clinical studies (ASTRAL-1, ASTRAL-2, ASTRAL-3 and ASTRAL-4) evaluating a once-daily, fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF) with velpatasvir (VEL), an investigational pangenotypic NS5A inhibitor, for the treatment of genotype 1-6 chronic hepatitis C virus (HCV) infection"
Gilead Releases Phase 3 SVR Rates-Sovaldi/GS5816